SINTX Technologies Divests Subsidiary to Focus on Medical Device Innovation

The subsidiary sale from SINTX Technologies enables the company to develop innovative medical devices while creating improved financial resilience for accelerated healthcare product development.

On Thursday SINTX Technologies released news that its completely owned TA&T subsidiary transferred ownership to Tethon Corporation under its Tethon 3D brand name. SINTX decided to sell its subsidiary to establish enhanced financial stability and operational effectiveness which allows the organization to direct attention toward medical device industry high-growth opportunities.

The decision to sell TA&T to Tethon Corporation delivers up to $1.7 million in annual cost savings alongside liabilities reduction of $750,000. Through its dedication to silicon nitride-based bioceramic innovations the company will achieve substantial developments in the medical implant market. SINTX uses its silicon nitride solutions for human implants since 2008 and continues advancing its medical research with this technology to develop future healthcare products.

Eric K. Olson who serves as SINTX Technologies CEO declared that this deal represents a major directional shift inside the company’s strategic reorganization. A solid financial position allows SINTX to speed up its medical device product development and commercialization process.

SINTX Technologies experienced slight stock price decline during regular market hours but its stock price increased during after-hours trading to $4.85 on Nasdaq.